Founded in 2013 and headquartered in Guangzhou, China, LDEBIO is an innovative IVD company dedicated to advancing the diagnosis of immune mediated diseases. Pioneering in T-cell diagnosis, LDEBIO focuses on unmet diagnostic needs for immune mediated diseases using the propriety AIM technology.
The facility in Guangzhou headquarter houses cutting-edge research labs, certified manufacturing facilities for IVD reagents and instruments, marketing and sales, and administrative functions. In addition, LDEBIO also has AIMDX research center in Maryland, USA and Leide Clinical Service Lab in Guangzhou. The company operates in three business segments: in vitro diagnostics, RUO reagents and clinical diagnostic services for infectious diseases, cancers, organ transplantation and autoimmune diseases. LDEBIO’s products and Services have covered over 30 provinces in China and serviced hospitals, independent clinical labs, pharmaceutical and biotech companies.
LDEBIO management team is consist of experienced and accomplished professionals, and their career experiences range from managing global research and product development projects in major international companies and institutions, hospital management, business development, marketing and sales for in vitro diagnostics. The venture backed company has devoted major efforts for developing the next generation diagnostic technology for immune mediated disease and look for collaboration with international partners for global markets.
Recently, the AIMTB Assay produced by Leide Biosciences Co., Ltd. has obtained registration certificates issued by NMPA, and will be officially commercialize in China domestic market
Official WeChat Add：7D, Science & Technology Innovation Base, #80 Lanyue Road, Huangpu District, Guangzhou, P.R.China
